Company identity
Browse spinoutsCompany number 12369627
Company profile
UK company 12369627, incorporated on 18 December 2019.
Nevrargenics - novel drugs for neurodegenerative diseases
Developing novel treatments for neurodegeneration
Company number 12369627
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
Nevrargenics discovers and develops pharmaceuticals for neurodegenerative diseases.
RAR-M Therapeutics focuses on the development of dual-acting, Retinoic Acid Receptor-Modulators as lead potential drugs for developing a rational and effective new treatment regime for ALS and with the future goal of treatments for other neurodegenerative disorders such as Alzheimer's disease.
Company only started end of December 2019